FDA’s first clearance of AI for autonomous detection of diabetic retinopathy
A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices.
Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy.
The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.
IDx-DR exceeded all pre-specified superiority endpoints in sensitivity, the ability to correctly identify a patient with disease; specificity, the ability to correctly classify a person as disease-free; and imageability, or the capability to produce quality images of the retina and determine the severity of the disease.
“The AI system’s primary role is to identify those people with diabetes who are likely to have diabetic retinopathy that requires further evaluation by an eye-care provider. The study results demonstrate the safety of autonomous AI systems to bring specialty-level diagnostics to a primary care setting, with the potential to increase access and lower cost,” says Michael Abràmoff, MD, PhD, the Robert C. Watzke Professor of Ophthalmology and Visual Sciences with UI Health Care and principal investigator on the study. He is founder and president of IDx, the company that created the IDx-DR system and funded the study.
Early detection may prevent vision loss
More than 24,000 people in the United States lose their sight to diabetic retinopathy each year. Early detection and treatment can reduce the risk of blindness by 95 percent, but less than 50 percent of patients with diabetes schedule regular exams with an eye-care specialist.
In the study, 900 adult patients with diabetes—but no history of diabetic retinopathy—were examined at 10 primary care sites across the country. Retinal images of the patients were obtained using a robotic camera, with an AI assisting the operator in getting good quality images.
Once the four images were complete, the diagnostic AI then made a clinical diagnosis in 20 seconds. The diagnostic AI detects disease just as expert clinicians do, by having detectors for the lesions characteristic for diabetic retinopathy, including microaneurysms, hemorrhages, and lipoprotein exudates.
Camera operators in the study were existing staff of the primary care clinics, and not physicians or trained photographers.
“This was much more than just a study testing an algorithm on an image. We wanted to test it in the places where it will be used, by the people who will use it, and we compared it to the highest standard in the world,” says Abràmoff, who also holds faculty appointments in the UI College of Engineering.
AI measured against gold standard
Study participants also had retinal images taken at each of the primary care clinics using specialized widefield and 3D imaging equipment without AI and operated by experienced retinal photographers certified by the Wisconsin Fundus Photograph Reading Center (FPRC)—the gold standard in grading the severity of diabetic retinopathy.
Complete diagnostic data accomplished by both the AI system and FPRC readers was available for 819 of the original 900 study participants. FPRC readers identified 198 participants with more than mild diabetic retinopathy who should be further examined by a specialist; the AI was able to correctly identify 173 of the 198 participants with disease, resulting in a sensitivity of 87 percent. Among the 621 disease-free participants identified by FPRC readers, AI identified 556 participants, for a specificity of 90 percent. The AI had a 96 percent imageability rate: of the 852 participants who had an FPRC diagnosis, 819 had an AI system diagnostic output.
The Latest on: IDx-DR
via Google News
The Latest on: IDx-DR
- Artificial intelligence can detect eye diseaseon August 1, 2019 at 1:58 pm
IDx-DR, an autonomous artificial intelligence diagnostic system developed by Dr. Michael Abramoff to detect diabetic retinopathy, gained approval in 2018 from the U.S. Food and Drug Administration.
- New CPT Code for Automated Point-of-Care Retinal Imagingon June 25, 2019 at 6:42 am
The AMA’s CPT Editorial Panel has accepted a new category 1 CPT code for automated point-of-care retinal imaging, facilitating reimbursement of the IDx-DR exam IDx, a privately held artificial ...
- How artificial intelligence is helping to prevent blindnesson April 10, 2019 at 8:02 am
Abràmoff had long wondered whether a computer program could be used to screen people for eye disease. Over several decades, he developed IDx-DR, an artificial intelligence (AI) system that can tell in ...
- Diabetes Patients Now Being Tested with AI in More Settingson February 12, 2019 at 5:18 am
IDx-DR sees adoption across a number of healthcare settings, increasing patient access to an autonomous AI diagnostic system that detects a leading cause of blindness CORALVILLE, Iowa, Feb. 12, 2019 ...
- IDx and Topcon Join Forces to Scale AI-based Diagnostic Platform in the U.S. Marketon October 22, 2018 at 5:51 pm
As part of the agreement, is granted exclusive rights to IDx-DR system, an autonomous AI system that instantly detects diabetic retinopathy in fundus images, exclusively with Topcon NW400, an easy to ...
- AI alone now making the diagnosison October 5, 2018 at 9:15 pm
For the first time, a computer can diagnose patients without a doctor's interpretation. In April 2018, the Food and Drug Administration approved IDx-DR, a tool driven by artificial intelligence that ...
- Idx raises $33 million for AI diagnostic systems that detect eye disease and other conditionson September 27, 2018 at 2:09 am
Iowa-based Idx is one startup using AI to detect early signs of specific medical conditions. Its first system, IDx-DR, is an AI diagnostic system that analyzes images of the retina for signs of ...
- AI Diagnostics Company IDx Secures Significant Funding From 8VC, Optum Ventureson September 26, 2018 at 7:07 am
We expect this investment to accelerate the adoption of IDx-DR, a unique and much-needed solution for the 30 million people with diabetes in the U.S. alone who need to be tested for diabetic ...
- University of Iowa Health Care First to Adopt IDx-DR in a Diabetes Care Settingon June 26, 2018 at 5:00 am
CORALVILLE, Iowa, June 26, 2018 /PRNewswire/ -- IDx, a privately-held AI diagnostics company, announced today that University of Iowa Health Care is the first U.S. healthcare system to use IDx-DR, an ...
- FDA Permits Marketing of IDx-DR for Automated Detection of Diabetic Retinopathy in Primary Careon April 12, 2018 at 4:21 am
CORALVILLE, Iowa, April 12, 2018 /PRNewswire/ -- IDx, a privately-held AI diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company's De Novo ...
via Bing News